Biology subjects

Mitcham, J.

Publications and source records attributed to Mitcham, J..

2 recordsLinked to original sources

bioRxiv2025

Ethanol inhibits dorsomedial striatum acetylcholine release

Alcohol use disorder (AUD) has severe adverse health and economic impacts totaling over $240 billion annually. Despite this, FDA approved treatments for AUD are limited. For this reason, further understanding of the neurobiological mechanisms in AUD is required for new treatments. An aspect of AUD involves deficits in behavioral flexibility that is similarly seen in animal models with depletion of dorsal striatal cholinergic interneurons (CINs). We found that acute EtOH (40 mM) inhibits the firing rate of dorsal striatal CINs, which are the primary source of acetylcholine (ACh) in the dorsal striatum. Additionally, we found through slice photometry recordings using an intensity-based ACh sensing fluorescent reporter (iAChSnFR) that acute EtOH (40 mM) inhibits dorsal striatal ACh release. In accord, in vivo fiber photometry with iAChSnFR also showed inhibition of ACh release following acute EtOH (2 g/kg ip). To induce EtOH dependence in mice, we used the chronic intermittent EtOH (CIE) vapor exposure model. Following CIE, we found that CIE-treated mice had a significant depression of ACh release compared to control mice in the dorsomedial but not dorsolateral striatum. Then, we performed stereological cell counts of CINs in CIE and control mice to examine the cause of this ACh deficit and found that CIE mice had a significant decrease in CINs in the dorsomedial but not dorsolateral striatum. In conclusion, our data show that EtOH inhibits dorsal striatal cholinergic signaling in a subregion specific manner that may contribute to AUD related behaviors.

neuroscience↗

bioRxiv2020

Quantification of discrete gut bacterial strains following fecal transplantation for recurrent Clostridioides difficile infection demonstrates long-term stable engraftment in non-relapsing recipients

Fecal Microbiota Transplantation (FMT), while successful for the treatment of recurrent Clostridioides difficile (rCDI) infection, lacks a quantitative identification of the discrete bacterial strains that transmit and stably engraft in recipients, and their association with clinical outcomes. Using >1,000 unique bacterial strains isolated and sequenced from a combination of 22 FMT donors and recipients, we develop a statistical approach Strainer to detect and track sequenced bacterial strains from low depth metagenomic sequencing data. On application to 14 FMT interventions, we detect stable and high engraftment of [~]71% of gut microbiota strains in recipients at even 5-years post-transplant, a remarkably durable therapeutic from a single administration. We found differential transmission and engraftment efficacy across bacterial taxonomic groups over short and long-time scales. Although [~]80% of the original pre-FMT recipient strains were eliminated by the FMT, those strains that remain persist even 5 years later, along with newer strains acquired from the environment. The precise quantification of donor bacterial strains in recipients independently explained the clinical outcomes of early and late relapse. Our framework identifies the consistently engrafting discrete bacterial strains for use in Live Biotherapeutic Products (LBP) as a safer, scalable alternative to FMT and enables systematic evaluation of different FMT and LBP study designs.

immunology↗